618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster I

4q Copy Neutral Loss of Heterozygosity and KMT2A Partial Tandem Duplication Identified By Chromosomal Genomic Array Testing (CGAT) Correlated with Decreased Overall Survival in Acute Myeloid Leukemia (AML)

ACSL4-Associated Lipid Metabolism Is a Distinct Therapeutic Vulnerability in KMT2A-Rearranged Acute Myeloid Leukemia

Aberrant Expression of Human Endogenous Retrovirus K9-Derived Elements Is Associated with Better Clinical Outcome of Acute Myelocytic Leukemia

Adult AML Patients with NUP98 Fusions Are Frequently Therapy-Related, and Are Associated with Monocytic Differentiation, Recurring Mutations in NRAS, DNMT3A and WT1 and Poor Outcome

Bone Marrow Failure in AML: Residual Neutrophils and Erythroblasts Are Derived By Differentiation from the AML

Clonal Evolution of TP53 Configurations with Treatment Predict Prognosis in Myeloid Neoplasms

Combination with Palbociclib Overcomes Venetoclax Resistance Mechanisms and Outperforms Single Agent Efficacy in Acute Myeloid Leukemia

Comparison of Anti-PD1, Anti-CTLA4 and Anti-TIM3 in Treatment of AML Patients with Single-Cell Transcriptomics Displays Different Effects on Immune Subtypes

Detection of KMT2A Partial Tandem Duplication in Myeloid Samples By Pacbio® Long Read Sequencing

Efficacy of the Peptide Drug Conjugates Melflufen and OPDC3 in Venetoclax Resistant Acute Myeloid Leukemia

Enhanced Validation of the FLT3-like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in FLT3-ITD Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi Trial

Genomic Landscape and Clonal Hematopoiesis Dynamics in Patients with Ovarian Cancer during PARP Inhibitors Treatment: Preliminary Results of a Prospective Longitudinal Study

Identification of Prognostic Signatures and Potential New Therapies in NPM1 Mutant Adult Acute Myeloid Leukemia Patients Using Proteomics

Inflammatory Biomarkers Predict Response and Survival in Chemotherapy-Ineligible and Untreated Acute Myeloid Leukemia Patients Receiving Venetoclax-Azacytidine As Front-Line Therapy

Inflammatory Transcriptional Signature Can Discriminate De Novo and Secondary AML

Integrated Single-Cell Long-Read and Short-Read Sequencing Reveals Critical Molecular Characteristics in Pediatric Acute Myeloid Leukemia

MLL5-Driven Leukemic Transformation Is Linked to Chromatin Remodeling and Can be Targeted with ATRA in Combination with PARP1 Inhibition

Multimodal Atlas of Paired Diagnosis and Relapse AML Reveals Surface Antigens for Multi-Specific Immunotherapy

Optical Genome Mapping As Standard-of-Care in Acute Leukemia: Diagnostic and Clinical Impacts 10 Months Post-Implementation

Optical Genome Mapping Reclassifies Patients with Intermediate Risk Acute Myeloid Leukemia

Predictors of Response and Rational Combinations for the Novel MCL-1 Inhibitor MIK665 in Acute Myeloid Leukemia

Prognostic Significance of Wilms’ Tumor 1 Gene Mutations in Acute Myeloid Leukemia: Risk Stratification and Survival Outcomes

Single-Cell Transcriptome Analysis Reveals the Novel Subtypes and Therapeutic Implications of T-Lymphoid/Myeloid Mixed-Phenotype Acute Leukemia

Single-Cell Transcriptomic Analyses Reveal Distinctive Immune Features between Childhood and Adult Acute Myeloid Leukemia

Uncovering Therapeutic Resistance in BPDCN through Single-Cell Transcriptome Profiling

p53 Immunohistochemistry As a High-Specificity Biomarker to Predict Allelic State and Overall Survival in Myelodysplastic Syndrome or Acute Myeloid Leukemia with Mutated TP53